Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab effects on lymph node and synovial inflammation in systemic lupus erythematosus
NL-OMON51447Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of belimumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Differences in lymph node cellular composition and functional aspects. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON51447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51447.